RegeneRx Biopharmaceuticals, Inc. Receives Patent for Reversal of Skin Aging in Japan

BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Alternext:RGN) announced today that it received notice of patent allowance from the Japanese Patent Office for “Inhibition or Reversal of Skin Aging by Actin-Sequestering Peptides”. This patent covers use of thymosin ß4 (Tß4) for promoting improvement of skin conditions including elasticity, and reduction and lightening of age-related skin abnormalities.